Chemo combo promising for pancreatic neuroendocrine tumors

July 13, 2012
Chemo combo promising for pancreatic neuroendocrine tumors
The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors, according to a study published online July 9 in the Journal of Clinical Oncology.

(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.

Jennifer A. Chan, M.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a phase II study in which they treated 34 patients with NETs (56 percent carcinoid; 44 percent pancreatic NETs) with in combination with bevacizumab.

The researchers found that the combination of temozolomide and bevacizumab correlated with expected grade 3 to 4 toxicities, including lymphopenia (53 percent) and thrombocytopenia (18 percent). The radiographic response rate was 15 percent overall, and was 33 percent for patients with pancreatic NETs, compared with 0 percent for those with carcinoid tumors. Progression-free survival was a median of 11.0 months (14.3 months for pancreatic NETs versus 7.3 months for carcinoid tumors). Overall survival was a median of 33.3 months (41.7 months for pancreatic NETs versus 18.8 months for carcinoid tumors).

"Temozolomide and bevacizumab can be safely administered together in patients with advanced NETs, and the combination regimen appears promising for patients with pancreatic NETs," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including and Schering-Plough/Merck, which funded the study and manufacture bevacizumab and temozolomide.

Explore further: Adding erlotinib to bevacizumab/chemoradiotherapy regimen for pancreatic cancer safe, tolerable

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012

(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Bevacizumab active in HIV-linked Kaposi's sarcoma

March 20, 2012

(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

Pancreatectomy OK without downstaging from therapy

May 25, 2012

(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published online May ...

Bevacizumab doesn't up overall survival in prostate cancer

March 27, 2012

(HealthDay) -- For men with metastatic castration-resistant prostate cancer (mCRPC), the addition of bevacizumab (B) to docetaxel plus prednisone (DP) is not associated with improved overall survival (OS), but does improve ...

Recommended for you

Study: Colonoscopy after 75 may not be worth it

September 26, 2016

(HealthDay)—A colonoscopy can find and remove cancerous growths in the colon, but it may not provide much cancer prevention benefit after the age of 75, a new study suggests.

Research finds talc doesn't cause cancer; juries disagree

September 26, 2016

Two lawsuits ended in jury verdicts worth $127 million. Two others were tossed out by a judge who said there wasn't reliable evidence that the talc in Johnson & Johnson's iconic baby powder causes ovarian cancer. So who's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.